2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116826
    Buramate 4663-83-6 98%
    Buramate exhibits neuroprotective and anticonvulsant activities.
    Buramate
  • HY-116859
    Ro 14-7437 78756-03-3 98%
    Ro 14-7437 is a potent and selective potentiating antagonist of Midazolam.
    Ro 14-7437
  • HY-116881
    SCH 57790 221660-80-6 98%
    SCH 57790 is a selective antegonist for muscarinic M2 receptor, which increases acetylcholine release, and thus improves cognitive performance. SCH 57790 reverses Scopolamine (HY-N0296)-induced memory deficits in mice, without significant toxicity (100 mg/kg).
    SCH 57790
  • HY-116908
    SB-272183 216058-27-4 98%
    SB-272183 is a selective 5-HT1A, 5-HT1B and 5-HT1D receptor antagonist. In addition, SB-272183 is also a potent and selective ligand for 5-HT1A, 5-HT1B and 5-HT1D receptors in human recombinant and native tissues with pKi values of 8.0, 8.1 and 8.7, respectively. SB-272183 can be used in antidepressant research.
    SB-272183
  • HY-116910
    CPP-115 640897-20-7 98%
    CPP-115 is a GABA transaminase inactivator with higher affinity and lower retinal toxicity than Vigabatrin (HY-15399). CPP-115 increases brain GABA levels by inhibiting GABA transaminase catabolism. CPP-115 can be used in the study of drug addiction and infantile spasms.
    CPP-115
  • HY-116916
    Acetophenazine 2751-68-0 98%
    Acetophenazine, a phenothiazine derivative, is an antipsychotic agent. Acetophenazine primarily blocks dopamine D2 receptors in the brain. Acetophenazine can be used for researching psychotic disorders such as schizophrenia and anxious depression.
    Acetophenazine
  • HY-116927
    KW-7158 214764-26-8 98%
    KW-7158 is a putative afferent nerve inhibitor that can depress vesica-vascular reflexes in rats. KW-7158 is an inhibitor of nucleoside transporter-1 (ENT1/SLC29A1) and acts as an antagonist for overactive bladder (OAB).
    KW-7158
  • HY-116942
    2002-H20 351520-91-7 98%
    2002-H20 is an inhibitor of Aβ42-induced cytotoxicity, with the activity of reducing the cytotoxicity of Alzheimer's disease Aβ peptide by binding to it. 2002-H20 protects cells and reduces Aβ toxicity by promoting fibril formation, possibly by accelerating Aβ aggregation. The screening method of 2002-H20 effectively identifies compounds that reduce Aβ toxicity and presents potential inhibitory leads.
    2002-H20
  • HY-117046
    AVN-101 1025725-91-0 98%
    AVN-101 is a potent, brain-penetrant and orally active 5-HT7 receptor antagonist (Ki of 153 pM), with slightly lesser potency toward 5-HT6, 5-HT2A, and 5HT-2C receptors (Ki values of 2.04 nM, 1.56  nM, and 1.17  nM, respectively). AVN-101 also exhibits a rather high affinity toward histamine H1 (Ki of 0.58 nM) and adrenergic α2A, α2B, and α2C (Ki= 0.41-3.6 nM) receptors. AVN-101 can be studied in such diseases as general anxiety disorders, depression, schizophrenia, Alzheimer’s disease, and multiple sclerosis.
    AVN-101
  • HY-117059
    SK609 hydrochloride 1092797-77-7 99.83%
    SK609 hydrochloride is a dopamine D3 receptor (D3R) selective agonist with an EC50 of 1109 nM. SK609 hydrochloride has the potential for parkinson research.
    SK609 hydrochloride
  • HY-117091
    DDD-028 1538586-09-2 98%
    DDD-028 is a potent non-opioid, non-cannabinoid analgesic which attenuates neuropathic and inflammatory pain without the possible side effects or abuse potential associated with opioid or cannabinoid activities. DDD-028 can be utilized in analgesic research.
    DDD-028
  • HY-117099
    TMB-8 53464-72-5 98%
    TMB-8 is a novel Ca 2+ antagonist. TMB-8 may exert inhibitory effects in smooth muscle by blocking Ca 2+ release from intracellular bound stores.
    TMB-8
  • HY-117132
    YM-202074 299900-83-7 98%
    YM-202074 is a selective, allosteric metabotropic glutamate receptor type 1 (mGluR1) antagonist with high affinity. YM-202074 binds to the allosteric site of rat mGluR1 with a Ki of 4.8 nM. YM-202074 fumarate also inhibits mGluR1-mediated inositol phosphate production in rat cerebellar granule cells with an IC50 of 8.6 nM. YM-202074 has potent neuroprotective effects in transient MCA (tMCA) occlusion rat models.
    YM-202074
  • HY-117162
    S 1432 24932-86-3 98%
    S 1432 is a central nervous system depressant with anticonvulsant and muscle relaxant effects. S 1432 significantly reduces acetylcholine levels in the striatum inhibits convulsions induced by pentylenetetrazol. S 1432 can be used in the development of psychotropic drugs.
    S 1432
  • HY-117176
    KRP-199 221164-28-9 98%
    KRP-199 (compound 14h) is an α-amino-3-hydroxy-5-methylisoxazolepropionic acid receptor (AMPA-R) antagonist (Ki=16 nM) with high potency and selectivity for AMPA-R in vitro and good neuroprotective effects in vivo. KRP-199 can be used in the study of neurodegenerative diseases.
    KRP-199
  • HY-117223
    GEA 857 120493-42-7 98%
    GEA 857 is a structural analog of the Serotonin (HY-B1473A) uptake blocker Alaproclate (HY-164011). GEA 857 enhances responses induced by muscarinic receptor agonists by inhibiting certain calcium-dependent potassium channels on membranes, a blockade that can enhance or prolong the muscarinic cholinergic effects. GEA 857 can be used in research on neurodegenerative diseases.
    GEA 857
  • HY-117248
    SR-3737 1164153-37-0 98%
    SR-3737 is a JNK3 and p38 inhibitor (IC50: 12 and 3 nM).
    SR-3737
  • HY-117251
    LP-403812 1142050-84-7 98%
    LP-403812 is a high affinity proline transporter (PROT) inhibitor that produces dose-dependent inhibition of hPROT (IC50=0.11 μM; Ki=0.12 μM) and also inhibits the activity of mouse brain synaptosomal mPROT with the same potency (IC50=0.23 μM). LP-403812 can be used to study the function of PROT in the brain.
    LP-403812
  • HY-117281
    Moexipril 103775-10-6 98%
    Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects-.
    Moexipril
  • HY-117284
    Eucatropine 100-91-4 98%
    Eucatropine is a potent muscarinic acetylcholine receptor (mAChR) inhibitor with an IC50 value of 0.583 μM. Eucatropine is an anticholinergic agent.
    Eucatropine
Cat. No. Product Name / Synonyms Application Reactivity